✦ LIBER ✦

Phase I clinical and pharmacokinetic study of trabectedin and cisplatin given every three weeks in patients with advanced solid tumors

✍ Scribed by Sessa, Cristiana; Conte, Gianluca; Christinat, Alexandre; Cresta, Sara; Perotti, Antonella; Gallerani, Elisa; Lardelli, Pilar; Kahatt, Carmen; Alfaro, Vicente; Iglesias, Jorge L.; Fernández-Teruel, Carlos; Gianni, Luca

Book ID: 125358909
Publisher: Springer US
Year: 2013
Tongue: English
Weight: 202 KB
Volume: 31
Category: Article
ISSN: 0167-6997
DOI: 10.1007/s10637-013-9942-y

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I clinical and pharmacokinetic stu

Phase I clinical and pharmacokinetic study of trabectedin and cisplatin in solid tumours

✍ C. Sessa; S. Cresta; C. Noberasco; G. Capri; E. Gallerani; F. De Braud; M. Zucch 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 125 KB

Phase I and pharmacokinetic study of tra

Phase I and pharmacokinetic study of trabectedin 3-hour infusion every three weeks in patients with advanced cancer and alteration of hepatic function

✍ Beatriz Pardo, Ramón Salazar, Eva Ciruelos, Hernán Cortés-Funes, Margarita Garcí 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 368 KB

A Phase I study of raltitrexed and pacli

A Phase I study of raltitrexed and paclitaxel given every 3 weeks to patients with solid tumors

✍ Everett E. Vokes; Boon C. Goh; Donna Bertucci; Nicholas J. Vogelzang; Sridhar Ma 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 66 KB 👁 2 views

## BACKGROUND. Raltitrexed is a novel thymidylate synthase inhibitor with single agent activity in colorectal, nonsmall cell lung, and breast carcinomas. The recommended Phase II dose of raltitrexed administered as a single agent is 3 mg/m 2 every 3 weeks. Paclitaxel also has a broad spectrum of a

A phase I and pharmacokinetic study of p

A phase I and pharmacokinetic study of paclitaxel poliglumex and cisplatin in patients with advanced solid tumors

✍ Claire F. Verschraegen; Keith Skubitz; Adil Daud; Andrzej P. Kudelka; Ian Rabino 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 310 KB

Phase I study of cisplatin, irinotecan,

Phase I study of cisplatin, irinotecan, and epirubicin administered every 3 weeks in patients with advanced solid tumours

✍ Chen, X; Oza, A M; Kusenda, Z; Yi, Q-L; Kochman, D; Moore, M J; Davis, A J; Siu, 📂 Article 📅 2003 🏛 Nature Publishing Group 🌐 English ⚖ 127 KB

Phase I dose-escalating study of ES-285

Phase I dose-escalating study of ES-285 given as a three-hour intravenous infusion every three weeks in patients with advanced malignant solid tumors

✍ C. Massard, R. Salazar, J. P. Armand, M. Majem, E. Deutsch, M. García, A. Oaknin 📂 Article 📅 2012 🏛 Springer US 🌐 English ⚖ 591 KB